Compare PII & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PII | BLLN |
|---|---|---|
| Founded | 1954 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Recreational Games/Products/Toys | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 1994 | N/A |
| Metric | PII | BLLN |
|---|---|---|
| Price | $55.01 | $80.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $58.08 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.0M | 281.7K |
| Earning Date | 04-28-2026 | 03-04-2026 |
| Dividend Yield | ★ 4.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,152,000,000.00 | N/A |
| Revenue This Year | $1.36 | $45.96 |
| Revenue Next Year | $4.40 | $30.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $31.40 | $61.96 |
| 52 Week High | $75.25 | $138.70 |
| Indicator | PII | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 51.76 |
| Support Level | $52.79 | $80.39 |
| Resistance Level | $60.28 | $83.20 |
| Average True Range (ATR) | 2.21 | 6.77 |
| MACD | 0.53 | 1.35 |
| Stochastic Oscillator | 45.83 | 49.68 |
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to pontoon and deck boat users. It is slated to divest its Indian motorcycle brand to Carolwood in the first quarter of 2026. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.